I am a healthcare professional in the UK
I am a patient or member of the public
Real world experiences of using LIVTENCITY®<span class="custom-triangle-down-icon"></span> (maribavir)
Real world experiences of using LIVTENCITY▼® (maribavir)
Clinicians share and discuss their experiences of using LIVTENCITY
Featured in this video:
• Prof Karl Peggs (Professor of Transplant Science and Cancer Immunotherapy, University College London Hospitals)
• Dr Mark Harber (Consultant Nephrologist with Special Interest in Transplantation, Royal Free Hospital)
• Dr Adnan Sharif (Consultant Nephrologist with Special Interest in Transplantation, University Hospitals Birmingham)
• Mr Colin Wilson (Consultant Transplant and Hepatobiliary Surgeon, Newcastle Hospitals)
Brightcove Video
A case study presentation of managing post-transplant CMV
Featured in this video:
• Dr Mark Harber (Consultant Nephrologist with Special Interest in Transplantation, Royal Free Hospital)
Brightcove Video
Book a meeting
Click this link to discuss the information on this page further with a Takeda representative.
You might be interested in
1 minute
download
This concise guide to LIVTENCITY® (maribavir) is designed for clarity and ease of use. It summarises key insights from the Phase 3 SOLSTICE trial, including efficacy outcomes, safety data, and practical dosing guidance.
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
5 minutes
Key efficacy outcomes from clinical trials evaluating LIVTENCITY in patients with post-transplant CMV, including virologic response and treatment comparisons.
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
